A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Trial Profile

A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms CLARITY EXTENSION
  • Sponsors EMD Serono
  • Most Recent Events

    • 27 Jun 2017 Results of an integrated analysis from three studies (ORACLE-MS, CLARITY, and CLARITY Extension) presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Longitudinal (48 weeks) evaluation of peripheral blood lymphocyte subtypes from patients of ORACLE-MS, CLARITY and CLARITY Extension; results presented at the 3rd Congress of the European Academy of Neurology
    • 27 Jun 2017 Results assessing the absolute lymphocyte count in patients treated with cladribine 3.5mg/kg using pooled data (n=685) from CLARITY and CLARITY Extension and PREMIERE registry along with data from patients randomised to placebo (n=435) in CLARITY and followed up in CLARITY Extension and PREMIERE, presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top